← All Sponsors
SPONSOR

Celgene

Total Trials
5
Recruiting
5
Phases
Phase 2, Phase 3, Phase 2, Phase 3
Conditions studied: AgitationAlzheimer DiseaseMyelodysplastic Syndromes (MDS)Beta-thalassemiaMyeloproliferative Neoplasm(MPN)-Associated MyelofibrosisBeta-ThalassemiaNeoplasmsMultiple Sclerosis Spasticity
NCT06808984 Phase 2
Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Agitation
United States View Trial →
NCT04064060 Phase 3
Recruiting

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Myelodysplastic Syndromes (MDS)
United States, Australia, Belgium View Trial →
NCT04143724 Phase 2
Recruiting

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Beta-Thalassemia
United States, China, Germany View Trial →
NCT03435796 Phase 2, Phase 3
Recruiting

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Neoplasms
United States, Australia, Austria View Trial →
NCT06782490 Phase 2
Recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Multiple Sclerosis Spasticity
United States, Australia, Canada View Trial →